Mirum Pharmaceuticals Inc [MIRM] stock is trading at $53.39, up 2.99%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The MIRM shares have gain 4.44% over the last week, with a monthly amount glided 6.21%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Stifel started tracking the stock with Buy rating on April 17, 2024, and set its price target to $48. On December 18, 2023, H.C. Wainwright reiterated its Buy rating and revised its price target to $58 on the stock. Morgan Stanley initiated its recommendation with a Overweight and recommended $60 as its price target on November 13, 2023. Cantor Fitzgerald started tracking with a Overweight rating for this stock on October 24, 2023, and assigned it a price target of $50.
Mirum Pharmaceuticals Inc [MIRM] stock has fluctuated between $36.86 and $54.78 over the past year. Currently, Wall Street analysts expect the stock to reach $57.25 within the next 12 months. Mirum Pharmaceuticals Inc [NASDAQ: MIRM] shares were valued at $53.39 at the most recent close of the market. An investor can expect a potential return of 7.23% based on the average MIRM price forecast.
Analyzing the MIRM fundamentals
Mirum Pharmaceuticals Inc [NASDAQ:MIRM] reported sales of 379.25M for the trailing twelve months, which represents a growth of 61.20%. Gross Profit Margin for this corporation currently stands at 0.77% with Operating Profit Margin at -0.2%, Pretax Profit Margin comes in at -0.2%, and Net Profit Margin reading is -0.2%. To continue investigating profitability, this company’s Return on Assets is posted at -0.11, Equity is -0.34 and Total Capital is -0.14. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.36.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Mirum Pharmaceuticals Inc’s Current Ratio is 3.22. Also, the Quick Ratio is 3.04, while the Cash Ratio stands at 1.66. Considering the valuation of this stock, the price to sales ratio is 6.97, the price to book ratio is 11.32.
Transactions by insiders
Recent insider trading involved Howe Jolanda, SVP, GLOBAL CONTROLLER, that happened on Jul 02 ’25 when 564.0 shares were sold. SVP, GLOBAL CONTROLLER, Howe Jolanda completed a deal on Jul 03 ’25 to sell 477.0 shares. Meanwhile, Officer JOLANDA MARIE HOWE bought 477.0 shares on Jul 03 ’25.
